



# Hypoglycosylation of dystroglycan due to T192M mutation: A molecular insight behind the fact



Simanti Bhattacharya, Amit Das, Semanti Ghosh, Rakhi Dasgupta\*, Angshuman Bagchi\*

Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, Nadia – 741235 WB, India

## ARTICLE INFO

### Article history:

Accepted 23 November 2013

Available online 18 December 2013

### Keywords:

Laminin1

Alpha dystroglycan

Molecular modeling

Protein–protein interactions

Molecular docking simulation

Dystroglycanopathy

## ABSTRACT

Abnormal glycosylation of dystroglycan (DG), a transmembrane glycoprotein, results in a group of diseases known as dystroglycanopathy. A severe dystroglycanopathy known as the limb girdle disease MDDGC9 [OMIM: 613818] occurs as a result of hypoglycosylation of alpha subunit of DG. Reasons behind this has been traced back to a point mutation (T192M) in DG that leads to weakening of interactions of DG protein with laminin and subsequent loss of signal flow through the DG protein. In this work we have tried to analyze the molecular details of the interactions between DG and laminin1 in order to propose a mechanism about the onset of the disease MDDGC9. We have observed noticeable changes between the modeled structures of wild type and mutant DG proteins. We also have employed molecular docking techniques to study and compare the binding interactions between laminin1 and both the wild type and mutant DG proteins. The docking simulations have revealed that the mutant DG has weaker interactions with laminin1 as compared to the wild type DG. Till date there are no previous reports that deal with the elucidation of the interactions of DG with laminin1 from the molecular level. Our study is therefore the first of its kind which analyzes the differences in binding patterns of laminin1 with both the wild type and mutant DG proteins. Our work would therefore facilitate analysis of the molecular mechanism of the disease MDDGC9. Future work based on our results may be useful for the development of suitable drugs against this disease.

© 2014 Elsevier B.V. All rights reserved.

## 1. Introduction



Muscular dystrophy (MD) stands for inherited genetic disease characterized by progressive degeneration and weakening of skeletal muscle affecting the control for muscular rhythm and functions (Shieh, 2013). Again muscular dystrophies generated owing to aberrant glycosylation of alpha-subunit of dystroglycan are collectively called dystroglycanopathies (Godfrey et al., 2011). Muscular dystrophy dystroglycanopathy of limb girdle, type C (MDDGC9, OMIM: 613818) is an autosomal recessive muscular disorder, characterized by severe mental retardation, delayed motor development and severe cognitive impairments in affected patients (Hara et al., 2011; Tabebordbar et al., 2013). Studies with diseased patients have revealed that a missense point mutation in human dystroglycan protein (DG) is the key abnormality behind this disease (Dinçer et al., 2003; Hara et al., 2011). DG is a trans-membrane protein found in muscle, brain, neuronal junctions

and epithelial cells (Henry and Campbell, 1999; Ibraghimov-Beskrovnaya et al. 1992; Tisi et al., 2000; Yamada et al., 1994). The precursor DG molecule, translated from a single mRNA, is being cleaved posttranslationally into alpha subunit ( $\alpha$ -DG) and beta subunit ( $\beta$ -DG) (Bozic et al., 2004; Henry and Campbell, 1999).  $\alpha$ -DG, the extra-cellular peripheral glycoprotein part, remains non-covalently attached to  $\beta$ -DG (Dinçer et al., 2003; Hara et al., 2011).  $\alpha$ -DG receives signals from a series of ligand molecules which include laminin, argin, perlecan and many more (Hohenester et al., 1999).  $\alpha$ -DG contains two globular domains, viz., domain1 (amino acid residues 30–315) and domain2 (amino acid residues 486–654) which are separated by bristled mucin like domain (amino acid residues 316–485), the highly glycosylated part of the protein (Henry and Campbell, 1999; Moore and Winder, 2012). On the other hand,  $\beta$ -DG remains associated with the membrane (Fig. 1); thereby interacting with the cytosolic actin network through a number of downstream effector partners, like dystrophin in muscle cells (Ilsley et al., 2001). They altogether form dystrophin dystroglycan complex (DGC) which is involved in a wide variety of cellular processes (Bozic et al., 2004) like membrane stability, cellular adhesion and intracellular signal propagations (Yurchenco, 2011). It also acts as an axis through which the extracellular matrix (ECM) is tightly coupled to the cellular actin cytoskeleton (Henry and Campbell, 1996). DG is the central part of the DGC system, which requires proper glycosylation at specified positions and proper ligand molecules to interact (Sciandra et al., 2003). In the case of the disease MDDGC9, there is hypoglycosylation of  $\alpha$ -DG by LARGE

**Abbreviations:** MD, muscular dystrophy; DG, dystroglycan; MDDGC9, muscular dystrophy dystroglycanopathy of limb girdle, type C; OMIM, online mendelian inheritance in man;  $\alpha$ -DG, alpha dystroglycan;  $\beta$ -DG, beta dystroglycan; DGC, dystrophin dystroglycan complex; ECM, extracellular matrix; LARGE, like-acetylglucosaminyltransferase; LG 4–5 domain, laminin G like domain 4 and 5; PDB, protein data bank; BLAST, basic local alignment search tool; WT, wild type; MT, mutant.

\* Corresponding authors. Tel.: +90 51948843; fax: +91 33 2582 8282.

E-mail addresses: [rdgag@gmail.com](mailto:rdgag@gmail.com) (R. Dasgupta), [angshuman\\_bagchi@yahoo.com](mailto:angshuman_bagchi@yahoo.com) (A. Bagchi).



Download English Version:

<https://daneshyari.com/en/article/5906078>

Download Persian Version:

<https://daneshyari.com/article/5906078>

[Daneshyari.com](https://daneshyari.com)